Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Nutr Food Res ; 58(8): 1610-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25044667

ABSTRACT

SCOPE: The influence of excess α-tocopherol (α-T) on tissue depletion of phylloquinone (PK) and menaquinone-4 (MK-4) was evaluated. METHODS AND RESULTS: Rats (n = 5 per group) were fed deuterium-labeled PK (2 µmol/kg diet) for 17 days, thereby labeling the conversion from deuterium-labeled PK to d4-MK-4. Then they were injected subcutaneously daily for the last 7 days with saline, vehicle, or α-T (100 mg/kg body weight). α-T injections (i) increased α-T concentrations by tenfold in liver, doubled them in plasma and most tissues, but they were unchanged in brain; (ii) increased the α-T metabolite, carboxyethyl hydroxychromanol (α-CEHC) concentrations: >25-fold in liver and kidney, tenfold in plasma and lung, and 50-fold in heart; brain contained detectable α-CEHC (0.26 ± 0.03 nmol/g) only in α-T-injected animals; and (iii) depleted most tissues' vitamin K. Compared with vehicle-injected rats, brains from α-T rats contained half the total vitamin K (10.3 ± 0.5 versus 21 ± 2 pmol/g, p = 0.0002) and one-third the d4-MK-4 (5.8 ± 0.5 versus 14.6 ± 1.7 pmol/g, p = 0.0002). Tissues with high PK concentrations (liver, 21-30 pmol/g and heart, 28-50 pmol/g) were resistant to K depletion. CONCLUSION: We propose that α-T-dependent vitamin K depletion is likely mediated at an intermediate step in MK-4 production; thus, tissues with high PK are unaffected.


Subject(s)
Liver/drug effects , Vitamin K 1/antagonists & inhibitors , Vitamin K 2/analogs & derivatives , Vitamin K Deficiency/chemically induced , Vitamins/adverse effects , alpha-Tocopherol/adverse effects , Animals , Biotransformation , Brain/drug effects , Brain/metabolism , Deuterium , Injections, Subcutaneous , Kidney/drug effects , Kidney/metabolism , Liver/metabolism , Male , Neurons/drug effects , Neurons/metabolism , Organ Specificity , Rats, Sprague-Dawley , Vitamin K 1/metabolism , Vitamin K 2/antagonists & inhibitors , Vitamin K 2/metabolism , Vitamin K Deficiency/blood , Vitamin K Deficiency/metabolism , Vitamins/administration & dosage , Vitamins/metabolism , Vitamins/pharmacokinetics , alpha-Tocopherol/administration & dosage , alpha-Tocopherol/metabolism , alpha-Tocopherol/pharmacokinetics
2.
Mol Nutr Food Res ; 57(10): 1785-93, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23650179

ABSTRACT

SCOPE: The objective of this study was to investigate the initial catabolic step of vitamin E and K metabolism, the ω-hydroxylation by human cytochrome P450 4F2 (CYP4F2). METHODS AND RESULTS: Tocopherol (T) metabolism was compared using rat liver slices incubated with deuterated (d6)-RRR-α-T (d6-α-T), racemic 2S-α-T (2S, 4'RS, 8'RS α-T, 2S-α-T), or d2-γ-T (d2-γ-T). Following comparable uptake of each T by liver slices, twice as much 13'-OH-T was produced from 2S-α-T or d2-γ-T (39 ± 15 or 42 ± 5 pmol/g liver, respectively) as from d6-α-T (17 ± 2, p < 0.01). Kinetic studies were conducted using insect microsomes expressing human CYP4F2 incubated with d4-phylloquinone (d4-PK), d6-RRR-α-T, d3-SRR-α-T, or d2-γ-T. CYP4F2 demonstrated similar apparent maximal velocities (Vmax) when either of the α-Ts were used as substrates, which were less than the apparent d4-PK Vmax (p < 0.0002), while the CYP4F2 catalytic efficiency toward d4-PK (15.8 Vmax/Km) was five times greater than for α-Ts. Vitamin K had no effect on vitamin E catabolism, while vitamin E slightly decreased the d4-PK Vmax. CONCLUSION: CYP4F2 discriminates between Ts and PK in vitro, but α-T does not apparently increase PK ω-hydroxylation by this mechanism.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Dietary Supplements , Vitamin K 1/metabolism , alpha-Tocopherol/pharmacology , Adenosine Triphosphate/metabolism , Animals , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme System/genetics , Cytochrome P450 Family 4 , Humans , Hydroxylation/drug effects , In Vitro Techniques , Liver/drug effects , Liver/metabolism , Male , Microsomes, Liver/metabolism , Rats , Rats, Sprague-Dawley , Tandem Mass Spectrometry
3.
Mol Nutr Food Res ; 56(6): 912-22, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22707266

ABSTRACT

SCOPE: The mechanism for increased bleeding and decreased vitamin K status accompanying vitamin E supplementation is unknown. We hypothesized that elevated hepatic α-tocopherol (α-T) concentrations may stimulate vitamin K metabolism and excretion. Furthermore, α-T may interfere with the side chain removal of phylloquinone (PK) to form menadione (MN) as an intermediate for synthesis of tissue-specific menaquinone-4 (MK-4). METHODS AND RESULTS: In order to investigate these hypotheses, rats were fed phylloquinone (PK) or menadione (MN) containing diets (2 µmol/kg) for 2.5 weeks. From day 10, rats were given daily subcutaneous injections of either α-T (100 mg/kg) or vehicle and were sacrificed 24 h after the seventh injection. Irrespective of diet, α-T injections decreased MK-4 concentrations in brain, lung, kidney, and heart; and PK in lung. These decreases were not accompanied by increased excretion of urinary 5C- or 7C-aglycone vitamin K metabolites, however, the urinary α-T metabolite (α-CEHC) increased ≥ 100-fold. Moreover, α-T increases were accompanied by downregulation of hepatic cytochrome P450 expression and modified expression of tissue ATP-binding cassette transporters. CONCLUSION: Thus, in rats, high tissue α-T depleted tissue MK-4 without significantly increasing urinary vitamin K metabolite excretion. Changes in tissue MK-4 and PK levels may be a result of altered regulation of transporters.


Subject(s)
Dietary Supplements/adverse effects , Vitamin E/adverse effects , Vitamin K 1/pharmacokinetics , Vitamin K 2/analogs & derivatives , Vitamin K 3/pharmacokinetics , ATP-Binding Cassette Transporters/metabolism , Administration, Oral , Animals , Biotransformation , Chromans/urine , Cytochrome P-450 Enzyme System/metabolism , Gene Expression Regulation/drug effects , Injections, Subcutaneous , Liver/enzymology , Liver/metabolism , Male , Propionates/urine , RNA, Messenger/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Tissue Distribution , Vitamin K 1/administration & dosage , Vitamin K 1/metabolism , Vitamin K 1/urine , Vitamin K 2/metabolism , Vitamin K 2/urine , Vitamin K 3/administration & dosage , Vitamin K 3/metabolism , Vitamin K 3/urine , alpha-Tocopherol/administration & dosage , alpha-Tocopherol/adverse effects , alpha-Tocopherol/metabolism , alpha-Tocopherol/urine
4.
Am J Dermatopathol ; 33(3): 244-50, 2011 May.
Article in English | MEDLINE | ID: mdl-21430507

ABSTRACT

Analysis of complex cutaneous reactions using animal models allows for the identification of essential or modulatory participants, that is, cyto- and chemokines or adhesion molecules. However, complex whole animal modeling is bound to obscure some specific contributions of individual players. Mouse models suggest that expression of Fas ligand (FasL) by donor T cells is essential for the cutaneous acute graft-versus-host reaction (aGvHR), a major complication after allogeneic hematopoietic stem cell transplantation. The role of FasL/Fas in human cutaneous GvHR is not known. To understand the mechanisms of cytotoxicity and inflammation in human cutaneous GvHR, we developed an organotypic model using reconstructed human epidermis (RHE) that was exposed to FasL, gamma-interferon (IFNγ), or both. The model recapitulated key histological hallmarks of cutaneous aGvHR, including interface dermatitis, appearance of cytoid bodies, hypergranulosis, and expression of ICAM-1. Cytoid body formation and expression of ICAM-1 were attributable entirely to IFNγ, whereas hypergranulosis was triggered by FasL. Both FasL and IFNγ triggered vacuolar degeneration of keratinocytes. The validity of the RHE model of GvHR was demonstrated by histological correlation with biopsied skin from patients with acute graft-versus-host disease. FasL and IFNγ each elicited potent and specific proinflammatory genomic responses in RHE. Inhibition of caspase activity dramatically augmented the FasL-induced proinflammatory responses, suggesting an "apoptosis-versus-inflammation" antagonism in cutaneous aGvHR and other lichenoid dermatoses.


Subject(s)
Dermatitis/metabolism , Dermatitis/pathology , Fas Ligand Protein/metabolism , Graft vs Host Disease/pathology , Interferon-gamma/metabolism , Dermatitis/genetics , Gene Expression , Gene Expression Profiling , Graft vs Host Disease/genetics , Graft vs Host Disease/metabolism , Humans , Organ Culture Techniques
5.
J Biol Chem ; 283(2): 919-28, 2008 Jan 11.
Article in English | MEDLINE | ID: mdl-17977827

ABSTRACT

Fas ligand (FasL) exerts potent proapoptotic and proinflammatory actions on epidermal keratinocytes and has been implicated in the pathogenesis of eczema, toxic epidermal necrolysis, and drug-induced skin eruptions. We used reconstructed human epidermis to investigate the mechanisms of FasL-induced inflammatory responses and their relationships with FasL-triggered caspase activity. Caspase activity was a potent antagonist of the pro-inflammatory gene expression triggered by FasL prior to the onset of cell death. Furthermore, we found that FasL-stimulated autocrine production of epidermal growth factor receptor (EGFR) ligands, and the subsequent activation of EGFR and ERK1 and ERK2 mitogen-activated protein kinases, were obligatory extracellular steps for the FasL-induced expression of a subset of inflammatory mediators, including CXCL8/interleukin (IL)-8, ICAM-1, IL-1alpha, IL-1beta, CCL20/MIP-3alpha, and thymic stromal lymphopoietin. These results expand the known physiological role of EGFR and its ligands from promoting keratinocyte mitogenesis and survival to mediating FasL-induced epidermal inflammation.


Subject(s)
Epidermis/physiopathology , ErbB Receptors/physiology , Fas Ligand Protein/physiology , Inflammation/physiopathology , Keratinocytes/physiology , Transcription, Genetic , Apoptosis , Cell Line , DNA Primers , Enzyme Activation , Extracellular Signal-Regulated MAP Kinases/genetics , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Infant, Newborn , Kidney , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/metabolism , Oligonucleotide Array Sequence Analysis , RNA Interference , RNA, Messenger/genetics , RNA, Small Interfering/genetics
6.
J Invest Dermatol ; 126(11): 2438-51, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16858424

ABSTRACT

Fas ligand (FasL) causes apoptosis of epidermal keratinocytes and triggers the appearance of spongiosis in eczematous dermatitis. We demonstrate here that FasL also aggravates inflammation by triggering the expression of proinflammatory cytokines, chemokines, and adhesion molecules in keratinocytes. In HaCaT cells and in reconstructed human epidermis (RHE), FasL triggered a NF-kappaB-dependent mRNA accumulation of inflammatory cytokines (tumor necrosis factor-alpha, IL-6, and IL-1beta), chemokines (CCL2/MCP-1, CXCL1/GROalpha, CXCL3/GROgamma, and CXCL8/IL-8), and the adhesion molecule ICAM-1. Oligomerization of Fas was required both for apoptosis and for gene expression. Inhibition of caspase activity abolished FasL-dependent apoptosis; however, it failed to suppress the expression of FasL-induced genes. Additionally, in the presence of caspase inhibitors, but not in their absence, FasL triggered the accumulation of CCL5/RANTES (regulated on activation normal T cell expressed and secreted) mRNA. Our findings identify a novel proinflammatory role of FasL in keratinocytes that is independent of caspase activity and is separable from apoptosis. Thus, in addition to causing spongiosis, FasL may play a direct role in triggering and/or sustaining inflammation in eczemas.


Subject(s)
Dermatitis/etiology , Eczema/etiology , Fas Ligand Protein/physiology , Keratinocytes/metabolism , Apoptosis/genetics , Caspase Inhibitors , Caspases/metabolism , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Cell Line , Chemokines/genetics , Chemokines/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Cytokines/genetics , Cytokines/metabolism , Dermatitis/genetics , Eczema/genetics , Epidermis/drug effects , Epidermis/metabolism , Epidermis/pathology , Fas Ligand Protein/pharmacology , Gene Expression/drug effects , Gene Expression Regulation , Humans , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Keratinocytes/chemistry , Keratinocytes/drug effects , NF-kappa B/antagonists & inhibitors , NF-kappa B/genetics , NF-kappa B/metabolism , Protein Biosynthesis/genetics , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL